Skip to content
naulon

Not checkedNot checked for notices yet.

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth

Mengmeng Niu, Jing Xu, Yang Liu and 27 more

Nature Communications · 2021

doi:10.1038/s41467-021-26222-x (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Aberrant EGFR activation is commonly found in non-small cell lung cancer (NSCLC). Here the authors show that E3 ubiquitin ligase FBXL2 targets EGFR and EGFR tyrosine kinase inhibitor (TKI)-resistant mutants for proteasome-mediated degradation to inhibit EGFR-driven NSCLC growth and TKI resistance.

Abstract licence: CC BY-NC-ND

Cited by papers we hold1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.